Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 40
- Profitability 95
- Business Quality 75
- Balance Sheet 65
- Cash Flow 35
Why this rating?
Health 45/100 — Speculative
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
Arcutis Biotherapeutics, Inc. (ARQT) is a Biotechnology company in the Healthcare sector. Compound Radar rates Arcutis Biotherapeutics, Inc. 45/100 (Speculative) due to high business quality, strong revenue growth, and elevated leverage.
Investment profile
- Quality High
- Growth Strong
- Balance Sheet Stretched
- Valuation Fair
Financial highlights
Valuation
- P/E 110.86
- Forward P/E 18.71
- EV/Revenue 6.21
Profitability
- Revenue Growth 59.3%
- Gross Margin 91.1%
- Operating Margin 12.7%
- Net Margin 6.1%
- ROE 15.9%
Financial strength
- Cash $238.55M
- Debt $114.14M
- Net Cash $124.42M
- Free Cash Flow $-16.31M
- Current Ratio 2.92
Similar companies
Peers in Biotechnology, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Aurinia Pharmaceuticals Inc. Biotechnology AUPH$16.07 83 Health 83 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Incyte Corporation Biotechnology INCY$124.40 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Catalyst Pharmaceuticals Inc Biotechnology CPRX$31.49 81 Health 81 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Alnylam Pharmaceuticals, Inc. Biotechnology ALNY$260.10 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Halozyme Therapeutics, Inc. Biotechnology HALO$108.31 77 Health 77 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Vertex Pharmaceuticals Incorporated Biotechnology VRTX$528.90 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Harmony Biosciences Holdings, Inc. Biotechnology HRMY$42.07 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- ACADIA Pharmaceuticals Inc. Biotechnology ACAD$27.58 75 Health 75 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Arcutis Biotherapeutics, Inc. (ARQT).